Shanghai RAAS SR604 Injection Proposed for CDE Care Program Pilot
Shanghai RAAS announced on August 31 that the CDE has proposed including its SR604 injection in the "Care Program - Extension" pilot, with public comment until September 4, 2026. The injection targets congenital factor VII deficiency. If formally included, it will receive close communication and professional guidance from the CDE during clinical development.
Shanghai RAAS announced on August 31 that the Center for Drug Evaluation (CDE) of the National Medical Products Administration has recently issued a public notice proposing to include the company's SR604 injection in the "Care Program - Extension" pilot project. The public comment period runs until September 4, 2026. One of the intended indications for the injection is congenital factor VII deficiency. If the injection is formally included in the pilot project after the comment period ends, SR604 will receive close communication and professional guidance from the CDE during its clinical drug development process.